Oyster Point Pharma Announces Expanded Patient Access to TYRVAYA®
The Company has also introduced in July expanded patient access programs to include more eligible patients.
- The Company has also introduced in July expanded patient access programs to include more eligible patients.
- The expansion of patient access to TYRVAYA comes as the Company continues to build upon its launch success.
- Our newly expanded patient access program aligns with our commitment to optimize access to TYRVAYA for as many eligible patients as possible.
- In October 2021, Oyster Point Pharma received FDA-approval for TYRVAYA (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease.